$LVTX

UTRECHT, The Netherlands and PHILADELPHIA, Feb. 01, 2022 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), an immuno-oncology company focused on developing its proprietary…

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 15, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company, today announced that the U.S.…

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- LAVA Therapeutics N.V. (Nasdaq: LVTX), a clinical-stage biotechnology company focused on developing bispecific…

UTRECHT, The Netherlands and PHILADELPHIA, Oct. 07, 2021 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by LAVA Therapeutics N.V. (Nasdaq: LVTX), please…